1. An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013. (4th November 2015) Authors: Ribrag, Vincent; Armand, Phillippe; Kuruvilla, John; Michot, Jean-Marie; Moskowitz, Craig H; Marinello, Patricia; Snyder, Ellen; Balakumaran, Arun; Shipp, Margaret A; Zinzani, Pier Luigi Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9980 (9th May 2015) Authors: Moskowitz, Craig H; Nademanee, Auayporn; Masszi, Tamas; Agura, Edward; Holowiecki, Jerzy; Abidi, Muneer H; Chen, Andy I; Stiff, Patrick; Gianni, Alessandro M; Carella, Angelo; Osmanov, Dzhelil; Bachanova, Veronika; Sweetenham, John; Sureda, Anna; Huebner, Dirk; Sievers, Eric L; Chi, Andy; Larsen,... Journal: Lancet Issue: Volume 385:Issue 9980(2015) Page Start: 1853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PET-adapted salvage therapy for Hodgkin's lymphoma – Authors' reply. Issue 5 (May 2015) Authors: Schöder, Heiko; Moskowitz, Craig H; Moskowitz, Alison J Journal: Lancet oncology Issue: Volume 16:Issue 5(2015:May) Page Start: e198 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Issue 3 (March 2015) Authors: Moskowitz, Alison J; Schöder, Heiko; Yahalom, Joachim; McCall, Susan J; Fox, Stephanie Y; Gerecitano, John; Grewal, Ravinder; Hamlin, Paul A; Horwitz, Steven; Kobos, Rachel; Kumar, Anita; Matasar, Matthew; Noy, Ariela; Palomba, M Lia; Perales, Miguel-Angel; Portlock, Carol S; Sauter, Craig; Shukl... Journal: Lancet oncology Issue: Volume 16:Issue 3(2015:Mar.) Page Start: 284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Issue 3 (March 2015) Authors: Moskowitz, Alison J; Schöder, Heiko; Yahalom, Joachim; McCall, Susan J; Fox, Stephanie Y; Gerecitano, John; Grewal, Ravinder; Hamlin, Paul A; Horwitz, Steven; Kobos, Rachel; Kumar, Anita; Matasar, Matthew; Noy, Ariela; Palomba, M Lia; Perales, Miguel-Angel; Portlock, Carol S; Sauter, Craig; Shukl... Journal: Lancet oncology Issue: Volume 16:Issue 3(2015:Mar.) Page Start: 284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087. (4th November 2015) Authors: Chen, Robert; Armand, Phillippe; Fanale, Michelle A; Ribrag, Vincent; Zinzani, Pier Luigi; Ricart, Alejandro D; Thompson, Seth; Balakumaran, Arun; Molin, Daniel; Shipp, Margaret A; Moskowitz, Craig H Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗